Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation reports developments across medical technology, patient monitoring and connected care. Company updates commonly center on Masimo SET pulse oximetry, noninvasive measurements, sensors, patient monitors, Masimo Hospital Automation and Masimo SafetyNet platforms, and telehealth or telemonitoring applications used in hospital and care settings.
Recurring MASI news also includes clinical evidence for monitoring performance, operating and financial results, non-GAAP financial materials, material agreements, shareholder voting matters, governance updates and capital-structure disclosures. The company’s public updates reflect its focus on healthcare monitoring technologies following the completed disposition of its consumer audio business.
Masimo (Nasdaq: MASI) shareholders approved the merger agreement with Danaher (NYSE: DHR) at a special meeting held May 1, 2026. Under the agreement, each Masimo share will be converted into $180.00 in cash at closing. The merger remains subject to customary closing conditions, including required regulatory approvals and clearances. Masimo expects the transaction to close in 2026 and to operate as an independent operating company within Danaher’s Diagnostics segment.
Masimo (NASDAQ: MASI) reported results from the NeoPODS neonatal study showing Masimo RD SET Neo pulse oximetry had mean SpO2−SaO2 bias −0.98% (95% CI −1.45% to −0.52%) and no occult hypoxemia cases among Black or Hispanic newborns. The prospective, NIH-funded study used objective skin pigmentation measures and 136 paired readings from 70 patients in two NICUs.
Researchers found no clinically meaningful or statistically significant bias by skin pigmentation or parent-reported race across tested classifications.
Masimo (Nasdaq: MASI) agreed to be acquired by Danaher (NYSE: DHR) for $180.00 per share in cash, representing total consideration of $9.9 billion. The boards of both companies unanimously approved the transaction.
Masimo will operate as a standalone business unit and brand within Danaher’s Diagnostics segment and is expected to close in the second half of 2026, subject to regulatory approvals. Masimo will report Q4 and full‑year 2025 results on Feb 26, 2026 but will not host an earnings call.
Danaher (NYSE: DHR) entered a definitive agreement to acquire Masimo (NASDAQ: MASI) for $180 per share in cash, implying an approximate $9.9 billion enterprise value including assumed debt and net of cash. The deal values Masimo at ~18x estimated 2027 EBITDA (15x including expected synergies).
Danaher expects Masimo to generate >$530 million EBITDA in 2027, deliver >$125 million annual cost synergies and >$50 million annual revenue synergies by year five, and be accretive to adjusted diluted EPS by $0.15–$0.20 in year one and ~ $0.70 in year five. Closing is anticipated in H2 2026, subject to regulatory clearances and Masimo shareholder approval.
Masimo (NASDAQ: MASI) will report fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after market close on Thursday, February 26, 2026.
The company will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET, led by CEO Katie Szyman and CFO Micah Young. Registration is required for dial-in details; a replay will be archived on the company website.
Masimo (NASDAQ: MASI) provided preliminary fourth-quarter and full-year 2025 financial results ahead of its Feb 26, 2026 full release. Q4 revenue is expected to be approximately $411 million, about 12% reported growth (11% constant currency). Q4 non-GAAP EPS is expected to be more than $1.54, and shipments of noninvasive technology boards and instruments are about 69,000. For full-year 2025, revenue is expected at approximately $1,523 million (about 9% growth) with non-GAAP EPS >$5.55 (the high end of guidance) and shipments of ~270,000. Guidance includes the estimated impact of new tariffs, one additional calendar week, and adjustments for discontinued product lines and distribution model changes.
Masimo (NASDAQ: MASI) said its management will present at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pacific time.
A live webcast of the presentation will be available on the company website at www.masimo.com, and a replay will be posted following the live presentation.
Masimo (NASDAQ: MASI) hosted its 2025 Investor Day and published a multi-year strategic roadmap through 2028 focused on patient monitoring, technology innovation, and commercial execution.
Key long-range financial targets: Revenue CAGR of 7%–10% through 2028; operating margin ~30% by 2028; adjusted EPS $8.00 by 2028; and cumulative operating cash flow ≈ $1 billion from 2026–2028. Masimo also reaffirmed its 2025 non-GAAP guidance: revenue $1,510–$1,530 million; non-GAAP operating profit $412–$424 million; and non-GAAP diluted EPS $5.40–$5.55.
A replay of the Investor Day webcast is available via the company’s investor site.
Masimo (NASDAQ: MASI) won a patent infringement verdict against Apple after an eight-day jury trial in the U.S. District Court for the Central District of California, with the jury awarding $634,313,913 in damages and finding infringement on all asserted claims.
The case is part of a long-running, multi-venue dispute between the companies; Knobbe Martens led Masimo's trial team and has secured other wins for Masimo, including an import ban on infringing Apple Watches at the U.S. International Trade Commission in early 2024.
Masimo (NASDAQ: MASI) announced a U.S. jury verdict in the Central District of California confirming the validity of Masimo Patent No. 10,433,776, finding that Apple infringed that patent and awarding Masimo $634 million in damages on November 15, 2025. Masimo said it is pleased with the outcome, thanked the court and jury, and emphasized the ruling as a significant win to protect its innovations and intellectual property. The company stated it remains committed to defending its IP rights going forward.